Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q2 CY2026, with sales up 13.1% year on year to $1.31 billion. The company expects the full year’s revenue to be around $5.22 billion, close to analysts’ estimates. Its non-GAAP profit of $0.70 per share was 15.1% above analysts’ consensus estimates.
Is now the time to buy DexCom? Find out by accessing our full research report, it’s free.
DexCom (DXCM) Q2 CY2026 Highlights:
- Revenue: $1.31 billion vs analyst estimates of $1.29 billion (13.1% year-on-year growth, 1.4% beat)
- Adjusted EPS: $0.70 vs analyst estimates of $0.61 (15.1% beat)
- Adjusted EBITDA: $421.3 million vs analyst estimates of $390.7 million (32.2% margin, 7.8% beat)
- The company slightly lifted its revenue guidance for the full year to $5.22 billion at the midpoint from $5.21 billion
- Operating Margin: 24.3%, up from 18.4% in the same quarter last year
- Organic Revenue rose 12% year on year (beat)
- Market Capitalization: $28.99 billion
Company Overview
Founded in 1999 and receiving its first FDA approval in 2006, DexCom (NASDAQ:DXCM) develops and sells continuous glucose monitoring systems that allow people with diabetes to track their blood sugar levels without repeated finger pricks.
Revenue Growth
A company’s long-term sales performance is one signal of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Luckily, DexCom’s sales grew at an impressive 18% compounded annual growth rate over the last five years. Its growth surpassed the average healthcare company and shows its offerings resonate with customers, a great starting point for our analysis.
Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. DexCom’s annualized revenue growth of 12.4% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. 
We can better understand the company’s sales dynamics by analyzing its organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don’t accurately reflect its fundamentals. Over the last two years, DexCom’s organic revenue averaged 12% year-on-year growth. Because this number aligns with its two-year revenue growth, we can see the company’s core operations (not acquisitions and divestitures) drove most of its results. 
This quarter, DexCom reported year-on-year revenue growth of 13.1%, and its $1.31 billion of revenue exceeded Wall Street’s estimates by 1.4%.
Looking ahead, sell-side analysts expect revenue to grow 10.7% over the next 12 months, a slight deceleration versus the last two years. Despite the slowdown, this projection is admirable and suggests the market is baking in success for its products and services.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
Adjusted Operating Margin
DexCom has managed its cost base well over the last five years. It demonstrated solid profitability for a healthcare business, producing an average adjusted operating margin of 19.3%.
Analyzing the trend in its profitability, DexCom’s adjusted operating margin rose by 13.9 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming in on its more recent performance, we can see the company’s trajectory is intact as its margin has also increased by 3.9 percentage points on a two-year basis. These data points are very encouraging and show momentum is on its side.
This quarter, DexCom generated an adjusted operating margin profit margin of 27.3%, up 8.1 percentage points year on year. This increase was a welcome development and shows it was more efficient.
Earnings Per Share
Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.
DexCom’s EPS grew at 28.2% compounded annual growth rate over the last five years, higher than its 18% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded.
Diving into the nuances of DexCom’s earnings can give us a better understanding of its performance. As we mentioned earlier, DexCom’s adjusted operating margin expanded by 13.9 percentage points over the last five years. On top of that, its share count shrank by 8.7%. These are positive signs for shareholders because improving profitability and share buybacks turbocharge EPS growth relative to revenue growth. 
In Q2, DexCom reported adjusted EPS of $0.70, up from $0.48 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects DexCom’s full-year EPS to grow 9.7% from $2.55 to $2.80.
Key Takeaways from DexCom’s Q2 Results
It was good to see DexCom beat analysts’ EPS expectations this quarter. We were also happy its revenue narrowly outperformed Wall Street’s estimates. Overall, this print had some key positives. The stock traded up 1.2% to $75.50 immediately after reporting.
Indeed, DexCom had a rock-solid quarterly earnings result, but is this stock a good investment here? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).